Core Insights - Caris Life Sciences has developed and validated a new version of Caris GPSai™, a deep learning AI tool that enhances diagnostic accuracy for cancers of unknown primary (CUP) and misclassified tumors [1][2][3] Group 1: Technology and Methodology - Caris GPSai™ utilizes deep learning and whole exome and whole transcriptome sequencing (WES/WTS) to improve the precision of tumor origin predictions and identify potential misdiagnoses [2][4] - The tool was trained on WES/WTS data from over 200,000 cases and can classify tumors into 90 categories, achieving 95.0% accuracy in non-CUP cases and reporting tissue of origin in 84.0% of CUP cases [3][4] Group 2: Clinical Impact - In clinical use over eight months, GPSai changed the diagnosis for 704 patients, with 86.1% of these cases impacting treatment eligibility based on Level 1 clinical evidence [4][5] - 53.6% of surveyed physicians reported altering treatment plans due to the insights provided by GPSai, highlighting its significant influence on patient care [4][5] Group 3: Company Overview - Caris Life Sciences is a leading AI TechBio company focused on precision medicine, utilizing advanced AI and machine learning to analyze complex molecular data for improved healthcare solutions [6][7] - The company aims to transform healthcare through comprehensive molecular profiling and has established a large-scale clinico-genomic database to support its initiatives [6][7]

报名：首届全球眼科大会 | 议程更新 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 合作伙伴征集：2025全球手术机器人大会 近日，生命科学公司Caris Life Sciences宣布，已完成一轮 1.68亿美元(合约12.2亿人民币) 的融资，以 支持其精准医疗平台的发展。 此次融资由投资者 Braidwell 领投，Perceptive Advisors、Woodline、Ghisallo、Millennium Management 和 First Light Asset Management 等也参与了投资。此轮融资使 Caris Life Sciences 自 2018 年以来的总筹资额达到 18.6 亿美元(合约135.98亿人民币) # 核心业务 Caris Life Sciences 成立于2008年， 公司致力于通过分子分析和人工智能技术，为癌症及其他复杂疾 病患者提供精准的诊断和治疗方案。 physician tests 业务 包括组织分析、血液分析以及人工智能相关服务。 分子分析技术： MI Profile™， 用于评估肿瘤组织中的 DNA、RNA 和蛋白 ...